Matinas Biopharma (MTNB)
(Delayed Data from AMEX)
$0.09 USD
0.00 (0.00%)
Updated Aug 27, 2024 03:18 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MTNB 0.09 0.00(0.00%)
Will MTNB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MTNB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MTNB
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
MTNB: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Matinas Biopharma Holdings, Inc. (MTNB)
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
Other News for MTNB
Buy Rating Affirmed: Matinas BioPharma’s Solid Financials and Promising Drug Development
Matinas BioPharma Holdings Inc (MTNB) Q2 2024 Earnings Call Transcript Highlights: Financial ...
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Here's the major earnings after the close today
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript